Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A dose-escalation and dose expansion Phase I clinical study of HQP1351 in patients with Chronic myeloid leukaemia (CML)

Trial Profile

A dose-escalation and dose expansion Phase I clinical study of HQP1351 in patients with Chronic myeloid leukaemia (CML)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HQP 1351 (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Nov 2019 According to an Ascentage Pharma media release, Xiaojun Huang, M.D. along with Qian Jiang, M.D., from Peking University People's Hospital are the principal investigators of this study.
    • 14 Nov 2019 According to an Ascentage Pharma media release, updated preliminary results from this study has been accepted for oral presentation at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition (7th-10th Dec 2019, in Orlando, Florida, United States).
    • 14 Nov 2019 Preliminary results (as of 27th May 2019, n=101) presented in an Ascentage Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top